BDC Venture Capital allocates $135 million more to healthcare innovation, broadens investment strategy

News - As part of its mandate to support Canadian entrepreneurs, BDC Venture Capital announced today it has allocated $135 million in new capital to direct venture investments in innovative healthcare companies. That brings its total direct commitment to the sector to $270 million. Recognizing a massive and growing market opportunity, the BDC Venture Capital Healthcare Fund will broaden its investment strategy and invest in technology, products and services that aim to dramatically improve global healthcare productivity, efficiency and patient outcomes.

Construction of the C-LAVIE Complex in Québec City - Héma-Québec takes on cell production

News - Héma-Québec, Québec City and the Government of Québec announce the construction of the C∙LAVIE complex, a cell production facility representing an investment of $21.5Mthat will be built in the Michelet innovation space within the territory of Québec City. The new building, with an area of 3,716 square metres, will provide a controlled environment (white rooms) that complies with good manufacturing practises (GMP), a pre-requisite for regulatory product approval. For the first few years, it will primarily be used to manufacture standardized cell and tissue products for clinical studies. Eventually, it will also ensure large-scale production of approved cellular medications.

Medicago Announces Receipt of Final Court Order and Regulatory Approvals for Arrangement with Mitsubishi Tanabe Pharma

News - Medicago is pleased to announce that the Superior Court of Quebec has granted its final order approving the previously announced plan of arrangement involving the Company, Mitsubishi Tanabe Pharma Corporation (MTPC) and 9284-9686 Québec Inc., a wholly-owned subsidiary of MTPC.

New hope for paraplegics and tetraplegics, a new drug that restores some walking capabilities being clinically tested in Canada

News - Nordic Life Science Pipeline launches a campaign to recruit 50 research subjects for the first clinical trials of SPINALONTM , an innovative oral tri-therapy aimed to trigger short episodes of rhythmic leg movements in severely spinal cord-injured subjects. Preclinical data strongly suggest that SpinalonTM is ideally suited to become a first-in-class therapy for spinal locomotor network activation, basic stepping movement generation and treadmill training in chronic, motor-complete, paraplegic and tetraplegic individuals classified as ASIA-A or ASIA-B. In 2009, the company signed an in-licensing agreement with UNIVERSITÉ LAVAL for the exclusive rights of developing Spinalon.

Aeterna Zentaris to Present at Upcoming Rodman & Renshaw Annual Global Investment Conference in New York

News - Aeterna Zentaris announces that the Company's President and CEO, David Dodd, will be presenting a corporate overview at the Rodman & Renshaw Annual Global Investment Conference on Monday, September 9, 2013, at 10:50 am (Eastern), in Room 7.02 of the Millennium Broadway Hotel, in New York.

Medicago Shareholders Approve Arrangement with Mitsubishi Tanabe Pharma Corporation

News - Medicago is pleased to annouce that its shareholders have approved, during today's special meeting of its shareholders, the resolution authorizing the previously announced plan of arrangement involving the Company, Mitsubishi Tanabe Pharma Corporation (MTPC) and 9284-9686 Québec Inc., a wholly-owned subsidiary of MTPC.

DiagnoCure Appoints Richard Bordeleau as Senior Advisor to the Board

News - DiagnoCure announces the appointment of Mr. Richard Bordeleau as Senior Advisor to the Company effective September 1, 2013. Mr. Bordeleau will act as an executive in residence and report directly to DiagnoCure’s board of directors. In collaboration with Company management, Mr. Bordeleau’s initial mandate will be to identify and implement short term actions aimed at increasing shareholder value, and also to evaluate mid to long term scenarios optimizing corporate value.

Aeterna Zentaris: First Patient Dosed for Phase 3 Registration Trial in Endometrial Cancer with Zoptarelin Doxorubicin (AEZS-108)

News - Aeterna Zentaris announces that the first patient has been recruited and dosed for the Phase 3 ZoptEC (Zoptarelin doxorubicin in Endometrial Cancer) trial in women with endometrial cancer resistant to platinum/taxane-based chemotherapy.

Aeterna Zentaris to Raise US$7.8 Million in Registered Direct Offering

News - Aeterna Zentaris announces that it has received commitments from institutional investors to purchase US$7.8 million of securities in a registered direct offering. Under the terms of a Securities Purchase Agreement, the Company will sell to such investors an aggregate of approximately 5.2 million common shares of its capital at a price of US$1.50 per share and issue warrants to acquire an aggregate of approximately 2.6 million common shares at an exercise price of US$1.85 per share.

Renowned Chemistry of love speaker organizes event in Québec City

News - The Québec City Convention Centre will welcome the International Symposium on Macrocyclic and Supramolecular Chemistry (ISMSC) 2018. More than 600 delegates will gather in Québec City July 8 to 12, 2018. Mr Normand Voyer*, chemist, professor in the Department of Chemistry at Université Laval and Director of PROTEO, convinced board members to hold the Symposium in Québec City. Mr Voyer is a renowned speaker and has given over 100 lectures to more than 20,000 people. The subject? The Chemistry of love.*


Jean-MichelGarroLife Sciences

More details


Subscribe to our newsletter for interesting news and information.

Print this page